CAM
BOLD

Cormorant Asset Management’s Boundless Bio BOLD Stock Holding History

Cormorant Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
+1,000,000
New +$1.54M 0.13% 49

Other funds holding BOLD

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Cormorant Asset Management's BOLD Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in Boundless Bio (BOLD) in Q2 2026: 1,000,000 shares worth $2.5M. The stake represents 0.13% of the portfolio and ranks #49 among its holdings.

34 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

  • Cormorant Asset Management held 1,000,000 shares of Boundless Bio worth $2.5M as of Q2 2026.
  • Boundless Bio was a new Cormorant Asset Management position in Q2 2026.
  • Boundless Bio made up 0.13% of Cormorant Asset Management's portfolio in Q2 2026, its #49 holding.
  • 34 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.